Amesite (AMST) Q2 2026 earnings summary

Executive summary

• Net loss of $1.37 million for the six months ended December 31, 2025, improved from $2.03 million loss in the prior year period.

• Revenue for the six months was $202,346, a significant increase from $24,010 year-over-year.

• Company pivoted focus from academic to healthcare markets, launching the NurseMagic™ app targeting nursing professionals.

• Management highlights substantial doubt about the ability to continue as a going concern due to recurring losses and cash burn.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $1.27 million at December 31, 2025, down from $2.43 million at June 30, 2025.

• General and administrative expenses decreased to $1.13 million for the six months, down from $1.44 million year-over-year.

• Technology and content development expenses were $268,000, down from $352,000 year-over-year.

• Sales and marketing expenses were $216,000, down from $293,000 year-over-year.

• Interest income for the six months was $32,600, up from $28,500 year-over-year.

Outlook and guidance

• Management plans to generate cash through financing transactions, including potential common stock offerings, but acknowledges these are subject to market conditions and not guaranteed.

• Uncertainty remains regarding the ability to maintain operations for the next twelve months.